Multi-targeted, multi-modality therapies and AI-driven innovation

Oncology R&D has advanced dramatically over the past 20 years, with the landscape now shifting towards multi-targeted, multi-modality therapies. But what are the key considerations for success in next-gen therapies?

Leading experts share their insights on:

Emerging oncology trends, including growing pipeline diversity and smarter, mechanism-driven development
Advances in multi-targeted, multi-modality therapies, including progress in drugging previously undruggable targets
How lean biotechs can balance investment and risk through efficient, biomarker-led precision trial design
The rising importance of early alignment with regulators and payers to support value-based care and commercialization

Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.

By accessing this content, you are permitting Pharma Ignite or a third party to contact you regarding the content (by phone or email).